Annual Report

Overview

The report records consolidated operating revenue of RMB 6,103,269,105.88 for 2024, alongside a sharp year-on-year decline. It highlights NMPA approvals for multiple cardiovascular intervention products, including biodegradable atrial septal defect occluders and transcatheter aortic valve systems. The workforce totaled 8,812 employees at period end.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Level
Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services